SCYNEXIS (NASDAQ: SCYX) and Tetraphase Pharmaceuticals (NASDAQ:TTPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.
Insider and Institutional Ownership
30.9% of SCYNEXIS shares are owned by institutional investors. Comparatively, 58.2% of Tetraphase Pharmaceuticals shares are owned by institutional investors. 4.0% of SCYNEXIS shares are owned by company insiders. Comparatively, 5.5% of Tetraphase Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares SCYNEXIS and Tetraphase Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
SCYNEXIS has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Tetraphase Pharmaceuticals has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for SCYNEXIS and Tetraphase Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SCYNEXIS currently has a consensus price target of $9.50, suggesting a potential upside of 421.98%. Tetraphase Pharmaceuticals has a consensus price target of $17.00, suggesting a potential upside of 172.44%. Given SCYNEXIS’s stronger consensus rating and higher probable upside, equities research analysts plainly believe SCYNEXIS is more favorable than Tetraphase Pharmaceuticals.
Valuation and Earnings
This table compares SCYNEXIS and Tetraphase Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tetraphase Pharmaceuticals||$5.14 million||62.42||-$77.48 million||($2.86)||-2.18|
SCYNEXIS has higher earnings, but lower revenue than Tetraphase Pharmaceuticals. SCYNEXIS is trading at a lower price-to-earnings ratio than Tetraphase Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
SCYNEXIS beats Tetraphase Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
SCYNEXIS Company Profile
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.